Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Food

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation f

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular se

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'

Palantir Technologies Inc (PLTR) shares jumped 16.1% in pre-market trading on upbeat Q2 results, wit

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark

Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta

Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protectio

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Or

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / A

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-r

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage

Ensysce Biosciences, Inc. (NASDAQ: ENSC - Get Free Report) was the target of a significant drop in s

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting

Ensysce Biosciences (NASDAQ: ENSC) shares are up on Friday as the company has initiated a review of

US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advanc

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics an

~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS N

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN

~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEG

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch FDA Aligned with ENSC Ma